Background: Clinical application of population pharmacokinetics (popPK) is of in-
| INTRODUCTION
Individual pharmacokinetic (PK) profiles based on population PK (popPK) modeling are not yet routinely employed by US hemophilia treatment centers (HTCs); however, the potential benefit of this patient-specific information to improve prophylaxis efficacy and reduce factor product consumption has gained awareness among patients, providers, and payers. [1] [2] [3] [4] Prophylaxis with factor concentrate is standard care for both adult and pediatric patients but is costly and challenging due to the frequency of intravenous infusions required. 5 Broad interpatient variability in clearance; increased interest in physical activity and sports participation; and the introduction of modified, extended half-life (EHL) factor concentrates impact the clinical utility of the traditional empiric approach to prophylaxis dosing. [6] [7] [8] Knowledge of a patient's PK profile may inform and help to individually tailor his or her prophylactic factor replacement regimen and thereby reduce the risk of longitudinal joint health concerns, pain management issues, and lost productivity compared to simply adjusting the prescribed prophylaxis based on bleed events. 4, 9 A prospective, randomized study comparing prophylaxis to episodic factor replacement demonstrated that as few as 1 to 2 bleeds were sufficient to be associated with radiographic joint changes. 10 The duration of time individuals spend with factor levels <1 IU/dL weekly correlates with an increased risk of bleed events (hemarthrosis and total bleeds). 11 Additionally, the physical demands placed on an individual through sports, physical activity, or job requirements may increase bleed risk using an empiric approach to prophylaxis. 7, 12 Individuals with faster clearance of exogenous factor replacement are at particular risk of being inadequately dosed by use of an empiric regimen based on mean adult PK data and potentially suffer preventable bleed events. Thus, understanding the impact of dose and infusion frequency on an individual patient's factor levels over time as well as patient adherence are key for a successful (minimal bleeding) prophylaxis regimen.
The application of Bayesian analytics to create popPK models in hemophilia established that a limited number of well-timed blood samples for PK analysis could yield similar output to full 11-sample PK curves, 13, 14 thus circumventing the impractical, sample intensive, model-independent strategy, designed for clinical trial use and evaluation of the bioequivalence among clotting factor concentrates. 15 Access to Web-based tools such as the Web Accessible Population
Pharmacokinetic Service-Hemophilia (WAPPS-Hemo, www.wappshemo.org) has enabled hemophilia providers to apply a popPK approach in their practices. 1, 16 WAPPS-Hemo has constructed specific models for most commercially available factor VIII (FVIII) (and factor IX) factor brands as well as a generic model capable of PK estimation for factor concentrate brands not included in the modeling data set. 17 Fat-free body mass, age, and factor brand have been found to significantly affect PK parameters and are included as covariates.
The WAPPS-Hemo data set has incorporated individuals spanning a broad age and weight continuum. 17, 18 The WAPPS-Hemo output for providers includes an estimate of the patient half-life for a given factor concentrate and estimated time to 5, 3, and 1 IU/dL factor activity levels. An interactive clinical calculator allows providers to simulate serial decay curves for a patient's prophylaxis regimen by manipulating a combination of dose, infusion frequency, and target trough level.
Although gaining momentum in the United States, the use of popPK has been applied more systematically in other regions such as Canada and the United Kingdom. [19] [20] [21] Provider uncertainty about how to incorporate this type of data into their established prescribing practices and the limited data demonstrating an impact on hemophilia health outcomes and economics in a routine care setting are barriers to the use of PK profiles in clinical practice. 22 The time and inconvenience of an extra laboratory visit or two and the time needed for PK data entry, interpretation, and explanation may also impede both provider and patient interest in pursuing a PK-tailored approach. This study aimed to assess the feasibility of implementing PK-tailored prophylaxis in routine clinical practice for hemophilia A and capturing a longitudinal assessment of patient-reported adherence, outcomes, and quality-of-life (QoL) factors. We also assessed provider use of the patient's PK profile and factors that contributed to clinical decision making for prescribed hemophilia prophylaxis.
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Essentials
• This study assesses the feasibility of implementing pharmacokinetic (PK)-tailored prophylaxis in routine clinical practice for hemophilia A and capturing longitudinal assessment of patient-reported outcomes.
• Motivations for obtaining PK profiles varied between patients and providers.
• Provider simulation of prophylaxis regimens with Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) clinical calculator supported clinical decision making and led to modification of prescribed infusion frequency rather than dose to achieve prophylaxis target levels.
• The visual outputs from WAPPS-Hemo facilitated provider communication of PK results and joint decision making for patient-tailored prophylaxis regimens. factor concentrates), use of nonfactor products for prophylaxis, a positive inhibitor titer (>0.6 BU/mL), or a known congenital bleeding disorder other than moderate or severe hemophilia A.
| METHODS
Feasibility was assessed by participant recruitment, success of PK profile creation, rate of completion of longitudinal assessments, and participant maintenance of an infusion and bleed log. As this was a feasibility study, no formal sample size calculation was undertaken; however, feasibility criteria were established (Table 1) assayed FVIII activities, assay methodology used). 28 Key considerations that impacted decision making for prescribed prophylaxis were collected as well as the changes in physician plan for prescribed prophylaxis following PK profile generation.
Descriptive statistics were used to report participant and prophylaxis regimen characteristics, provider use of the PK profile and WAPPS-Hemo interactive clinical calculator for regimen simulation, and measures of study feasibility. Patterns of treatment regimen parameter selection (dose, infusion frequency and target trough) using the clinical calculator were also reported using descriptive statistics. Note: Green, feasibility target met; amber, feasibility target not met but likely achievable with study design modification.
| RESULTS

| Assessment of feasibility
patient population. Table 1 reported maintaining logs; by week 12, this had decreased to 56%.
| Participant characteristics
Of the 18 eligible patients enrolled, 15 participants fulfilled both PK profile generation and completion of baseline clinical data for analysis ( Table 2 ). All patients had severe hemophilia A with a reported baseline FVIII activity <1 IU/dL. All but 1 patient was on a continuous prophylaxis regimen at the time of enrollment. A history of any positive titer inhibitor was reported in 28% of patients. Two of these patients had spontaneously resolving low-titer inhibitors; the remaining 3 had completed an immune tolerance induction regimen. At baseline assessment, nearly all patients (87%) reported regular participation in physical activity. Seven patients (47%) reported at least 1 active target joint. Seven patients (47%) had a PK estimate for an EHL factor concentrate, and the remainder were for an SHL product.
| Application of WAPPS-Hemo in clinical practice
All participants reported an interest in their individualized PK profile and specifically a desire to better understand changes in their factor levels over time to support participation in physical activities, a general interest in how their factor levels change over time after factor infusion, and an interest in decreasing the frequency of infusions needed for successful prophylaxis (Figure 1 ). Most providers (67%) ascribed patients' interest in PK to a general interest about how their factor activity levels changed over time; however, the majority also identi- Ultimately, 1 patient transitioned to emicizumab prophylaxis during the follow-up portion of the study; however, the remainder of patients did not have additional changes made to their prescribed prophylaxis regimens during the study.
| CONCLUSIONS
Our feasibility assessment suggests that, while a larger-scale study powered to evaluate the impact of PK-tailored prophylaxis on clinical and patent reported outcomes is achievable, modification to the study design is needed to attain target enrollment. This study has contributed to our understanding, from both a provider and a patient perspective, of how to incorporate individualized PK data into medical decision making for hemophilia A prophylaxis. In general, the population recruited for this study were young patients with hemophilia A, including children and younger adults. This may reflect the participating HTC composition or provider practice, or could reflect more interest in PK among younger patients. Also, younger children generally have more pristine joints and on average more rapid clearance, likely incentivizing both parents and providers to be additionally cautious with prophylaxis decisions.
Motivations for interest in PK studies varied between patients and providers. While participants consistently noted general interest in understanding the FVIII activity levels over time, there was also strong interest in optimizing levels for sports and athletic pursuits as well as minimizing infusion frequency. Providers also selected interest in a general understanding as their primary interest and highlighted their interest in optimizing factor levels for physical activity and improved bleed control. Providers seemed to underestimate patient interest in reducing infusion frequency but ranked minimizing time spent with FVIII activity levels <1 IU/dL as a priority. Our study participants reported either active target joints or regular participation in physical activity or, in some cases, both. A desire to better understand one's own rate of FVIII activity decay in either of these cases makes sense and provides a motivation for participating in a study such as this. Individuals without bleeding symptoms on prophylaxis may also benefit from having a PK profile. These patients potentially need even fewer infusions or lower factor dosing to provide adequate prophylaxis; however, engaging them in the extra steps needed for PK profile may be difficult without clear demonstration of potential benefit. to generate and analyze PK data on clinical and patient-reported outcome in clinical practice is needed. Data from this feasibility study will provide baseline data to inform power calculations for a prospective study as well as the number of HTCs needed to achieve target enrollment. Prospective evaluation of whether use of popPK profiles change factor concentrate use, reduce annualized bleed rates, and improve patient assessment of disease burden is important so that we do not unnecessarily add complexity to prescribed prophylaxis without adding clinical value. Additional assessment of patient characteristics and motivations for participating in PK studies may add clarity regarding patient subgroups that may particularly benefit from use of popPK in clinical practice and help HTCs understand how to best guide application of popPK into their routine practice. For a prospective interventional study, incorporation of a patient-facing tool for estimating blood factor activity levels (myWAPPS, www.myWAP PS.org), as a companion application to the WAPPS-Hemo-generated popPK profiles, may provide an educational element for patients and further support adherence to prophylaxis through the ability to individually tailor infusion timing based on estimated factor levels and activity-based bleed risk assessment.
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